CancerCare is a national nonprofit organization that provides free, professional support services for anyone affected by cancer.
Today, I listened along with over 850 other participants to a CancerCare Telephone Education Workshop describing updates on Chronic Myelogenous Leukemia (CML) from the American Society of Hematology (ASH) Annual Meeting. Below is a summary of what I learned.
Chronic myelogenous leukemia (CML) is a form of leukemia linked to a chromosome abnormality. This blood cancer occurs when genetic material is displaced from one chromosome to another. Parts of chromosome 9 and chromosome 22 switch places. This chromosomal translocation is known as the Philadelphia chromosome.
At the 48th annual ASH (American Society of Hematology) meeting that took place in December, leading hematologists presented the latest findings in research. CML can be treated with tyrosine-kinase inhibitors and there are exciting new findings about the success of clinical trials. Sometimes mutations occur that cause resistance to the tyrosine-kinase inhibitors used to treat CML. To overcome this resistance and to increase responsiveness to inhibitors, agents have been developed to block several cancer causing proteins.
Side effects of treatment include fluid retention and pleural effusion (fluid in the chest cavity), as well as fatigue and gastrointestinal problems.
Today, I listened along with over 850 other participants to a CancerCare Telephone Education Workshop describing updates on Chronic Myelogenous Leukemia (CML) from the American Society of Hematology (ASH) Annual Meeting. Below is a summary of what I learned.
Chronic myelogenous leukemia (CML) is a form of leukemia linked to a chromosome abnormality. This blood cancer occurs when genetic material is displaced from one chromosome to another. Parts of chromosome 9 and chromosome 22 switch places. This chromosomal translocation is known as the Philadelphia chromosome.
At the 48th annual ASH (American Society of Hematology) meeting that took place in December, leading hematologists presented the latest findings in research. CML can be treated with tyrosine-kinase inhibitors and there are exciting new findings about the success of clinical trials. Sometimes mutations occur that cause resistance to the tyrosine-kinase inhibitors used to treat CML. To overcome this resistance and to increase responsiveness to inhibitors, agents have been developed to block several cancer causing proteins.
Side effects of treatment include fluid retention and pleural effusion (fluid in the chest cavity), as well as fatigue and gastrointestinal problems.
No comments:
Post a Comment